CO6761366A2 - Composiciones farmacéuticas para el tratamiento de glioma maligno - Google Patents
Composiciones farmacéuticas para el tratamiento de glioma malignoInfo
- Publication number
- CO6761366A2 CO6761366A2 CO13163973A CO13163973A CO6761366A2 CO 6761366 A2 CO6761366 A2 CO 6761366A2 CO 13163973 A CO13163973 A CO 13163973A CO 13163973 A CO13163973 A CO 13163973A CO 6761366 A2 CO6761366 A2 CO 6761366A2
- Authority
- CO
- Colombia
- Prior art keywords
- treatment
- malignant glioma
- pharmaceutical compositions
- therapeutic agent
- radiation therapy
- Prior art date
Links
- 206010018338 Glioma Diseases 0.000 title abstract 2
- 208000029824 high grade glioma Diseases 0.000 title abstract 2
- 201000011614 malignant glioma Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 2
- 230000001472 cytotoxic effect Effects 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 238000001959 radiotherapy Methods 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 abstract 1
- 208000005017 glioblastoma Diseases 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- 229960004964 temozolomide Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2011050494 | 2011-02-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6761366A2 true CO6761366A2 (es) | 2013-09-30 |
Family
ID=45787254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO13163973A CO6761366A2 (es) | 2011-02-04 | 2013-07-10 | Composiciones farmacéuticas para el tratamiento de glioma maligno |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20130310407A1 (enExample) |
| EP (2) | EP2965757A1 (enExample) |
| JP (2) | JP5642892B2 (enExample) |
| KR (1) | KR101563069B1 (enExample) |
| CN (1) | CN103327975A (enExample) |
| AR (1) | AR085132A1 (enExample) |
| AU (1) | AU2012213036A1 (enExample) |
| BR (1) | BR112013019680A2 (enExample) |
| CA (1) | CA2823994A1 (enExample) |
| CL (1) | CL2013002193A1 (enExample) |
| CO (1) | CO6761366A2 (enExample) |
| EA (1) | EA201391131A1 (enExample) |
| IL (1) | IL227747A0 (enExample) |
| MA (1) | MA34952B1 (enExample) |
| MX (1) | MX2013008798A (enExample) |
| PH (1) | PH12013501461A1 (enExample) |
| SG (1) | SG192600A1 (enExample) |
| TN (1) | TN2013000333A1 (enExample) |
| TW (1) | TW201309298A (enExample) |
| WO (1) | WO2012104822A1 (enExample) |
| ZA (1) | ZA201306613B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2393117T3 (es) | 2005-09-12 | 2012-12-18 | Actelion Pharmaceuticals Ltd. | Composición farmacéutica estable que comprende una pirimidina-sulfamida |
| AU2010282744B2 (en) | 2009-08-10 | 2014-08-28 | Board Of Regents, The University Of Texas System | Treatment of brain metastases with inhibitors of endothelin receptors in combination with a cytotoxic chemotherapy agent |
| CN103397308A (zh) * | 2013-08-01 | 2013-11-20 | 光垒光电科技（上海）有限公司 | 用于mocvd设备的喷淋头 |
| TWI559928B (en) * | 2014-08-20 | 2016-12-01 | Academia Sinica | Methods for enhancing permeability to blood-brain barrier and uses thereof |
| KR101701619B1 (ko) | 2015-06-26 | 2017-02-01 | 건양대학교산학협력단 | 뇌교종 세포 치료를 위한 테모졸로마이드와 비타민 d가 포함된 조성물 |
| KR102574253B1 (ko) | 2020-12-15 | 2023-09-07 | 주식회사 시선테라퓨틱스 | 펩티드 핵산 복합체를 유효성분으로 함유하는 교모세포종 예방 또는 치료용 조성물 |
| CN115317604B (zh) * | 2022-08-11 | 2023-09-22 | 南京脑科医院 | 一种靶向胶质瘤的共载放疗增敏阳离子纳米制剂及其制备方法和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1693372A1 (en) | 2000-12-18 | 2006-08-23 | Actelion Pharmaceuticals Ltd. | Novel Sulfamides and their use as endothelin receptor antagonists |
| ES2393117T3 (es) | 2005-09-12 | 2012-12-18 | Actelion Pharmaceuticals Ltd. | Composición farmacéutica estable que comprende una pirimidina-sulfamida |
| WO2008111092A1 (en) * | 2007-03-09 | 2008-09-18 | Fresenius Kabi Oncology Limited | Crystalline temozolomide monohydrate and process for preparation thereof |
| MX2010008994A (es) * | 2008-02-20 | 2010-09-07 | Actelion Pharmaceuticals Ltd | Combinacion que comprende paclitaxel para el tratamiento del cancer de ovario. |
| AU2010282744B2 (en) * | 2009-08-10 | 2014-08-28 | Board Of Regents, The University Of Texas System | Treatment of brain metastases with inhibitors of endothelin receptors in combination with a cytotoxic chemotherapy agent |
-
2012
- 2012-02-03 TW TW101103560A patent/TW201309298A/zh unknown
- 2012-02-03 JP JP2013552318A patent/JP5642892B2/ja not_active Expired - Fee Related
- 2012-02-03 WO PCT/IB2012/050513 patent/WO2012104822A1/en not_active Ceased
- 2012-02-03 AR ARP120100357A patent/AR085132A1/es unknown
- 2012-02-03 PH PH1/2013/501461A patent/PH12013501461A1/en unknown
- 2012-02-03 US US13/983,383 patent/US20130310407A1/en not_active Abandoned
- 2012-02-03 EA EA201391131A patent/EA201391131A1/ru unknown
- 2012-02-03 MX MX2013008798A patent/MX2013008798A/es active IP Right Grant
- 2012-02-03 AU AU2012213036A patent/AU2012213036A1/en not_active Abandoned
- 2012-02-03 EP EP15178064.0A patent/EP2965757A1/en not_active Withdrawn
- 2012-02-03 CA CA2823994A patent/CA2823994A1/en not_active Abandoned
- 2012-02-03 SG SG2013058979A patent/SG192600A1/en unknown
- 2012-02-03 CN CN2012800059659A patent/CN103327975A/zh active Pending
- 2012-02-03 EP EP12706925.0A patent/EP2670405B1/en not_active Not-in-force
- 2012-02-03 BR BR112013019680A patent/BR112013019680A2/pt not_active IP Right Cessation
- 2012-02-03 KR KR1020137023170A patent/KR101563069B1/ko not_active Expired - Fee Related
- 2012-02-03 MA MA36217A patent/MA34952B1/fr unknown
-
2013
- 2013-07-10 CO CO13163973A patent/CO6761366A2/es not_active Application Discontinuation
- 2013-07-31 CL CL2013002193A patent/CL2013002193A1/es unknown
- 2013-08-01 IL IL227747A patent/IL227747A0/en unknown
- 2013-08-01 TN TNP2013000333A patent/TN2013000333A1/fr unknown
- 2013-09-03 ZA ZA2013/06613A patent/ZA201306613B/en unknown
-
2014
- 2014-10-28 JP JP2014219218A patent/JP2015057409A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR101563069B1 (ko) | 2015-10-23 |
| AR085132A1 (es) | 2013-09-11 |
| PH12013501461A1 (en) | 2019-03-22 |
| EP2670405A1 (en) | 2013-12-11 |
| AU2012213036A1 (en) | 2013-09-19 |
| TN2013000333A1 (en) | 2015-01-20 |
| MA34952B1 (fr) | 2014-03-01 |
| JP2015057409A (ja) | 2015-03-26 |
| CA2823994A1 (en) | 2012-08-09 |
| MX2013008798A (es) | 2013-10-17 |
| TW201309298A (zh) | 2013-03-01 |
| JP2014504636A (ja) | 2014-02-24 |
| KR20130118981A (ko) | 2013-10-30 |
| ZA201306613B (en) | 2015-04-29 |
| CN103327975A (zh) | 2013-09-25 |
| WO2012104822A1 (en) | 2012-08-09 |
| CL2013002193A1 (es) | 2014-05-09 |
| IL227747A0 (en) | 2013-09-30 |
| US20130310407A1 (en) | 2013-11-21 |
| BR112013019680A2 (pt) | 2016-10-11 |
| NZ615005A (en) | 2015-10-30 |
| JP5642892B2 (ja) | 2014-12-17 |
| EP2965757A1 (en) | 2016-01-13 |
| SG192600A1 (en) | 2013-09-30 |
| EA201391131A1 (ru) | 2013-12-30 |
| EP2670405B1 (en) | 2015-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202308495B (en) | Pharmaceutical compositions of therapeutically active compounds | |
| PH12016501139B1 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| PH12016501171A1 (en) | Peptidomimetic compounds and antibody-drug conjugates thereof | |
| CL2015001731A1 (es) | Compuestos inhibidores de autotaxina; composicion y combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como fibrosis, prurito, cancer, entre otras. | |
| NZ749217A (en) | Androgen receptor modulator and uses thereof | |
| CL2012000772A1 (es) | Compuestos derivados de hetorociclos carboxamidicos sustituidos, antagonista ar; composición farmacéutica que los comprende; y uso en el tratamiento del cáncer de próstata. | |
| MX381017B (es) | Compuestos peptidomiméticos y conjugados anticuerpo-fármaco de estos. | |
| CL2011003350A1 (es) | Compuestos derivados de heterociclo nitrogenados, moduladores pkm2; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer. | |
| BR112015016681A8 (pt) | uso de nanopartículas compreendendo paclitaxel e uma albumina, kit, medicamento, composição e forma de dosagem unitária para tratamento de câncer pancreático | |
| SV2015005115A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| CL2013000018A1 (es) | Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros. | |
| CL2013000016A1 (es) | Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer. | |
| CL2015002658A1 (es) | Derivados de 2, 3 - disustituto 1- acil -4 amino - 1,2,3,4 tetrahidroquinilina y su uso como inhibidores de bromodominio | |
| CL2015002767A1 (es) | Compuestos terapéuticos y composiciones | |
| UY36075A (es) | Derivados de tubulisina | |
| UY33984A (es) | Uso de 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas | |
| MX366899B (es) | Nuevos compuestos. | |
| CL2013001009A1 (es) | Compuestos heterociclicos fusionados; composicion farmaceutica que los comprende, y uso en el tratamiento de un trastorno proliferativo tal como cancer. | |
| IL258246B (en) | Isolidine compound, pharmaceutical compositions comprising same, their combinations with therapeutic agents for use in the treatment of cancer | |
| CL2015003595A1 (es) | Inhibidores/antiandrógenos novedosos de cyp17 | |
| CL2015001202A1 (es) | Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer. | |
| SV2012004192A (es) | Nuevo uso antitumoral de cabazitaxel | |
| PH12015502616A1 (en) | Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer | |
| CL2012003322A1 (es) | Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer. | |
| MX2013008175A (es) | Composiciones farmacéuticas para suministro tópico de fotosensibilizadores y usos de los mismos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |